Glenview Trust Co increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 0.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 178,040 shares of the company’s stock after purchasing an additional 933 shares during the period. Glenview Trust Co’s holdings in Merck & Co., Inc. were worth $16,193,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. grew its position in Merck & Co., Inc. by 2.3% in the 2nd quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock valued at $16,087,745,000 after purchasing an additional 4,397,580 shares during the period. State Street Corp lifted its stake in shares of Merck & Co., Inc. by 1.0% in the fourth quarter. State Street Corp now owns 116,493,884 shares of the company’s stock valued at $10,665,449,000 after buying an additional 1,196,724 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of Merck & Co., Inc. by 1.5% during the third quarter. Parametric Portfolio Associates LLC now owns 11,408,929 shares of the company’s stock valued at $960,404,000 after buying an additional 171,403 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Merck & Co., Inc. by 3.2% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,846,593 shares of the company’s stock valued at $913,066,000 after buying an additional 338,355 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Merck & Co., Inc. by 0.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 10,253,759 shares of the company’s stock valued at $863,162,000 after buying an additional 39,180 shares during the last quarter. 74.50% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently weighed in on MRK. Mizuho restated a “buy” rating on shares of Merck & Co., Inc. in a report on Wednesday, February 5th. Morgan Stanley lifted their price target on Merck & Co., Inc. from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Royal Bank of Canada reissued a “sector perform” rating and set a $92.00 price objective on shares of Merck & Co., Inc. in a report on Thursday, February 6th. ValuEngine downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Tuesday, January 14th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Merck & Co., Inc. has a consensus rating of “Buy” and an average price target of $95.75.

Merck & Co., Inc. stock traded up $0.08 during mid-day trading on Friday, reaching $82.05. 1,461,782 shares of the company’s stock were exchanged, compared to its average volume of 11,022,104. The business’s fifty day simple moving average is $88.70 and its 200 day simple moving average is $86.14. The firm has a market capitalization of $218.09 billion, a PE ratio of 21.53, a P/E/G ratio of 2.18 and a beta of 0.57. Merck & Co., Inc. has a one year low of $72.23 and a one year high of $92.64. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Wednesday, February 5th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.15 by $0.01. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.71 billion. Merck & Co., Inc. had a return on equity of 48.76% and a net margin of 21.01%. The business’s revenue was up 7.9% compared to the same quarter last year. During the same period last year, the firm posted $1.04 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 5.74 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a $0.61 dividend. This represents a $2.44 annualized dividend and a yield of 2.97%. The ex-dividend date is Friday, March 13th. Merck & Co., Inc.’s dividend payout ratio is 47.01%.

In other Merck & Co., Inc. news, EVP Julie L. Gerberding sold 102,073 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $89.34, for a total value of $9,119,201.82. Following the transaction, the executive vice president now directly owns 106,099 shares in the company, valued at $9,478,884.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.27% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: What does the Dogs of the Dow mean?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.